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Abstract
To elucidate the mechanism of anti-inflammatory effect of partial liquid ventilation (PLV),
cytokine concentration, surface CD11b, and macrophage expression were investigated in BALF.
The 30-minutes group was treated with gas ventilation (GV) for 30 minutes after intratracheal LPS
administration. The GV group was prepared in the same manner as the 30-minutes group, then the
GV was continued for the following 2 hours. The PLV group was treated in the same manner as
the 30-minutes group, and then received PLV with perflubron for the following 2 hours. Animals
were euthanized to receive BAL. The PLV group showed a tendency to have a higher concentration
than the GV group of TNF-alpha, MIP-2, and CINC-1 as measured by ELISA, although there
were no significant differences. The ratio of expressions of CD11b and macrophages to total
leukocytes were determined by flow-cytometry. There were no significant differences in the ratio
of CD11b-positive expression to acquired cells (GV: 63.6 +/- 8.4%, PLV: 60.5+/-5.4%, P=0.73).
However, the proportion of macrophages was significantly increased (GV: 5.6 +/-1.5, PLV: 14.0+/-
1.3, P=0.006). These results suggest that the anti-inflammatory effect of PLV is not caused by the
change in CD11b expression, and that PLV affects the proportion of macrophage among BALF
cells.
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 Partial Liquid Ventilation does not Aﬀect BALF TNF-α, MIP-2,
CINC-1 Concentrations, or CD11b Cell Surface Expression,
but does Increase Macrophage Proportion among BALF Cells in the Acute Phase of Rat LPS-Induced Lung Injury
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To elucidate the mechanism of anti-inﬂammatory eﬀect of partial liquid ventilation(PLV), cytokine concentration, surface CD11b, and macrophage expression were investigated in BALF. The 30-minutes group was treated with gas ventilation (GV) for 30 minutes after intratracheal LPS administration. The GV group was prepared in the same manner as the 30-minutes group, then the GV was continued for the following 2 hours. The PLV group was treated in the same manner as the 30-minutes group, and then received PLV with perﬂubron for the following 2 hours. Animals were euthanized to receive BAL. The PLV group showed a tendency to have a higher concentration than the GV group of TNF-α, MIP-2, and CINC-1 as measured by ELISA, although there were no signiﬁcant diﬀerences. The ratio of expressions of CD11b and macrophages to total leukocytes were determined by ﬂow-cytometry. There were no signiﬁcant diﬀerences in the ratio of CD11b-positive expression to acquired cells(GV:63.6±8.4 , PLV:60.5±5.4 , ＝0.73). However, the propor-
tion of macrophages was signiﬁcantly increased (GV:5.6±1.5, PLV:14.0±1.3, ＝0.006). These results suggest that the anti-inﬂammatory eﬀect of PLV is not caused by the change in CD11b expression, and that PLV aﬀects the proportion of macrophage among BALF cells.
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P artial  liquid ventilation (PLV) with perﬂuorocarbon(PFC)has been investigated as a treatment for acute respiratory distress syndrome
(ARDS)in both the experimental and clinical settings. It is evident that PLV improves gas exchange and pulmo-
nary compliance in experimental animals［1-6］. These beneﬁcial features have also been corroborated in a clinical
 
setting［1, 7-13］. Several in vitro studies have been reported. PFC exposed to alveolar macrophages produced less hydrogen peroxide［14］. Lipopolysacchar-
ide(LPS)-induced tumor necrosis factor-alpha(TNF-α),
interleukin-1, and interleukin-6 productions were inhibited in the PFC-exposed human macrophages［15］. Neutro-
phils exposed to PFC in vitro produce less hydrogen peroxide, and have a lower chemotactic response［16］.
Based on the ﬁndings in these previous studies, PLV apparently has some anti-inﬂammatory eﬀect. However,
the mechanisms of this eﬀect remain unknown. Although
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we consider it not necessary to prove the anti-
inﬂammatory eﬀect of PLV, we do need to investigate the mechanisms of the anti-inﬂammatory eﬀect of PLV.
We considered the following four hypotheses as mecha-
nisms of PLV. First, contact with PFC may aﬀect inﬂammatory cells such as neutrophils and macrophages that have already been activated and migrated into alveoli to change their function. Second, PFC may act as a physical barrier, lining the surface of alveolar epithelial cells then preventing the inﬂux of inﬂammatory cells or chemical mediators from interstitial space into the alveoli.
Third, PFC may also cover the surface of inﬂammatory cells that were activated and migrated into alveoli as a physical barrier, blocking further interaction for these cells. Fourth, PFC administered into the airway may lavage inﬂammatory chemical mediators such as cytokines from the distal airways, then remove them from the lung by suction that occurs during PLV, resulting in a lung-
protective eﬀect. Subsequently, we investigated CD11b cell surface marker up-regulation to verify these hypoth-
eses.
Neutrophil-mediated tissue injury is a common mecha-
nism underlying the development of organ dysfunction during acute lung injury including ARDS. A CD11b surface marker plays an important role for neutrophils when it is up-regulated, allowing ﬁrm adhesion with intercellular adhesion molecule-1 on the endothelial sur-
face, after which the migration or inﬁltration of neutro-
phils occurs. The neutrophils that have inﬁltrated and accumulated in the lungs release reactive oxygen species or proteases, then cause micro-endothelial injury and lung edema characterized by hyperpermeability. Will the con-
tact with PFC change the surface marker up-regulation for neutrophils migrating into alveoli in vivo? If some diﬀerence were observed in the cell surface marker up-regulation between the GV and the PLV groups, we might hypothesize that the PLV aﬀect on neutrophils that have already activated and migrated into the alveolar space is to inactivate their function. In that event, we could simply focus on the ﬁrst and the third hypotheses as the mechanisms of the anti-inﬂammatory eﬀect. In addition,
we investigated the macrophage population among bron-
choalveolar lavage(BAL)cells that is said to produce cytokines and chemokines. To our knowledge, there have been no previous reports on the number of macrophages in PLV. We undertook to study the cytokine concentra-
tion in bronchoalveolar lavage ﬂuid (BALF)to conﬁrm that cytokine concentration is attenuated in PLV. We
 
also tried to manifest the eﬀect of PLV in the early phase of inﬂammation after lung injury was induced in the lungs.
For this purpose, we chose two C-X-C chemokines,
macrophage inﬂammatory protein(MIP)-2 and cytokine-
induced neutrophil chemoattractant (CINC) -1, which shows its peak 90 to 120 minutes after lung injury,
neither of which had yet been investigated. We adopted a rat model of acute lung injury by intratracheal LPS administration, which induces rapid lung injury［17］, so that the peak time of TNF-α, MIP-2 and CINC-1 elevations could be easily assumed.
Materials and Methods
 
Male Wistar pathogen-free rats weighing 250-300 g (283.2±9.8 g, Japan SLC,
Hamamatsu, Japan)were anesthetized with 50 mg/kg of intraperitoneal sodium pentobarbital. An open tracheos-
tomy was performed and a 14-gauge angiocatheter
(Becton-Dickinson, CA, USA), which was connected to a three-way stopcock with a side adapter tube, was secured.
The rats were ventilated with a volume-controlled mechanical ventilator (Shinano seisakusho, model SN-
480-7), with tidal volume＝10 ml/kg, FiO?＝1.0, and respiratory rate＝30 breath/min. Pancronium bromide 0.1 mg was injected in the femoral muscle every hour.
After 15 minutes of gas ventilation, 10 mg/kg of LPS
(from Escherichia coli Serotype 0111:B4, Sigma Chemi-
cal Co., St. Louis, MO, USA)dissolved in 1 ml/kg of saline was administered intratracheally. All rats then received gas ventilation for the next initial 30 minutes.
Group 1(Negative control, n＝9):Rats were eutha-
nized at 30 minutes after LPS administration. This group, sacriﬁced prior to initiation of the 2-hour experi-
mental period, served as a“negative”control to identify the degree of inﬂammatory response. Group 2 (gas ventilation:GV, n＝11):GV continued to receive LPS for two more hours(2 hours and 30 minutes in total). No airway suction was performed. Group 3 (partial liquid ventilation:PLV, n＝11):Animals received administra-
tion of 8 ml/kg of Perﬂubron(Green Cross Co., Osaka,
Japan)as PFC over 3 minutes through the side port of the three-way stopcock 30 minutes after LPS administra-
tion. Just after the administration of perﬂubron, the side port of the stopcock was opened once to the outside air then closed again. This was to remove the extra air in the ventilator circuit, in order to prevent ventilator-associated
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lung injury that might have occurred in response to high tidal volume caused by the sum of the gas ventilator tidal volume and perﬂubron. PLV was then continued for 2 hours. No additional perﬂubron was administered and no suction from the lungs was performed during PLV. All animals underwent euthanasia at completion of the prepa-
ration by intraperitoneal pentobarbital overdose. Subse-
quent exsanguination was performed by incision of the abdominal aorta.
Immedi-
ately after euthanasia and exsanguination, 8-ml aliquots of phosphate-buﬀered saline (PBS, pH 7.4) were slowly infused in the lungs through the tracheostomy then withdrawn gently. No drainage or suction of perﬂubron or exudate in the airway was done before this lavage.
This lavage was repeated four times using the same syringe. The collected lavage ﬂuid was stored in a 50-ml tube on ice. The ﬂuid was centrifuged at 400×g for 5 minutes within several hours, and the cell-free super-
natants were stored in microcentrifuge tubes at －80 centigrade in a refrigerator for subsequent cytokine analy-
sis. The pellet was re-suspended in 10 mL of PBS.
Contaminating erythrocytes were lysed with 1 mL of NH?
Cl solution for 5 minutes and washed with PBS. After washing twice with PBS, the pellet was re-suspended in 10 mL of RPMI-1640(Nissho 87-640-0,Osaka, Japan)
with 1  fetal bovine serum. Total leukocyte cell count was performed by Toluidine blue-O stain. Cell diﬀerentiation analysis was not performed.
All animals received humane care in compliance with the“Principles of Laboratory Animal Care”included in the“Guide for the Care and Use of Laboratory Animals”
prepared by the National Academy of Science and pub-
lished by the National Institute of Health(National Insti-
tute of Health publication No. 85-23, revised 1985), and also with the“Guidelines for Animal Experiments of the Okayama University Medical School”.
α
BAL total protein concentration was mea-
sured by the Bradford method［18］. The concentrations of TNF-α, MIP-2, and CINC-1 in the BALF super-
natant were quantitated by Enzyme-linked immunosolvent assay (ELISA). A rat  TNF-α ELISA Kit
#KRC3010SB (BioSource International, Inc., CA,
USA), Rat MIP-2 ELISA Kit#KRC1022 (BioSource International, Inc., CA, USA), and Rat GRO/CINC measuring Kit-IBL(Immuno-Biological Laboratories Co.,
Ltd., Gunma, Japan)were used for the assays. Samples
 
were diluted with PBS within an appropriate range to achieve the same dilution ratio, because the concentra-
tions of the samples were out of range of measurement with the kit. The absorbance at 450 nm wavelength was measured by a microplate reader Immuno-mini NJ-2300
(System Instruments Co., Ltd., Tokyo, Japan). All samples were analyzed in duplicate using a blinded method.
BAL cells were harvested and analyzed for the expression of CD11b and for macrophage surface marker by ﬂow cytometry within the same day. A suspension containing about 1×10?of cells was used for each ﬂow cytometric analysis. The suspension was mixed with 1μg of FITC-conjugated mouse anti-rat CD11b monoclonal antibody (mAb, clone OX-42). One μg of FITC-
conjugated mouse anti-Rat IgG? isotypic control mAb
(clone R35-95)was added into another tube containing a suspension of cells from the same sample. These samples were incubated for 20 minutes at room temperature.
After washing 3 times with PBS, CD11b receptor expression was analyzed by a ﬂow cytometer FACS Calibur(Becton Dickinson, CA, USA). Ten thousand individual cells were captured in the cytometer using a neutrophil gate set for both forward scatter and side scatter. Fluorescence was measured using a FL-1 detec-
tor. The total number of CD11b positive cells was determined by assessing positive cells of isotypic control mAb (Fig. 1). The ratio of cells positive for CD11b expression to total cells was then compared between the two groups of GV and PLV.
For macrophage identiﬁcation, R-PE-conjugated mouse anti-rat macrophage subset mAb(clone HIS36)or R-PE-conjugated mouse anti-Rat IgG?κ, isotypic control mAb (clone R3-34) was used for analysis. A FL-2 detector was used for PE-conjugated mAbs, and no gate was used for this measurement of anti-rat macrophage subset mAb expression. The positive ratio of macrophage expression to total cells was determined using the same marker in a histogram that excluded positive cells of the isotypic control mAb(Fig. 2).
All mAbs were purchased from PharMingen (CA,
USA)via Fujisawa Pharmaceutical Co., Ltd. (Tokyo,
Japan).
Data are shown as mean±SEM. Statistical tests were carried out between the experimental groups of GV and PLV using the Mann-Whitney U test. Statistical signiﬁcance was
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 accepted at P＜0.05.
Results
 
All animals survived until the end of the experiment.
Bronchoalveolar lavage
 
ﬂuid (BALF) volumes for the three groups were as follows:negative control (LPS 30 min):31.9±0.1 ml,
GV:30±0.6 ml, PLV:30.2±0.3 ml. No signiﬁcant diﬀerences in BAL recovery volume were observed between GV and PLV groups.
BALF super-
Fig.1  Examples of ﬂow cytometry histograms are shown. Individual cells(n＝10000)were captured into a cytometer using a neutrophil gate. Fluorescence of FITC was measured using a FL-1 detector. In the GV sample(left), the ratio of cells positive for CD11b expression was determined using a marker(M1)in the histogram that excluded 99 % of the positive cells of the isotypic control. The same procedure was performed on the PLV sample(right)using marker(M2). These markers were determined for each sample, and the ratio of cells positive for CD11b to total cell number was calculated.
Fig.2  Examples of ﬂow cytometry histograms are shown. Individual cells(n＝10000)were captured into a cytometer. Fluorescence of PE was measured using a FL-2 detector. In the GV sample(left), the ratio of positive macrophage expression was determined using a marker
(M3)in the histogram that excluded 99 % of the positive cells of the isotypic control. The same procedure was performed on the PLV sample
(right)using marker (M4). These markers were determined for each sample, and ratio of cells showing positive anti-macrophage mAb expression to total cell number was calculated.
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 natant total protein per unit BALF volume was assessed.
Compared to the 30-minute ventilation group, PLV demonstrated about twice as much protein, and the GV group showed signiﬁcantly lower total protein concentra-
tion than that in the PLV group (LPS 30 min:0.37±
0.08, GV:0.60±0.03 vs. PLV:0.74±0.03, P＝
0.02)(Fig.3). Compared with the negative control group,
the GV and PLV groups demonstrated a signiﬁcant increase in TNF-α (LPS 30 min:637.5±70.0, GV:
19808.5±922.9 vs. PLV:21062.8±1816.3, P＝1.00)
(Fig. 4). The PLV group showed a tendency to have a higher TNF-αvalue than that in the GV group, though no statistical diﬀerence between two groups could be identiﬁed. The same tendency for higher TNF-αwas observed in both MIP-2 (LPS 30 min:398.8±64.7,
GV:14071.5±809.9  vs. PLV:16030.3±1663.9,
P＝0.64)(Fig. 5)and CINC-1(LPS 30 min:192.6±




Fig. 3  BALF total protein concentration per 1 ml of BALF is shown. BALF total protein concentrations were measured by the Bradford method. Although there was no diﬀerence in BALF recovery volume among the 3 groups, protein concentrations were standard-
ized by the volume here. The PLV group demonstrated a signiﬁcantly higher concentration than that in the GV group(LPS 30 min:0.37±
0.08, GV:0.60±0.03 vs. PLV:0.74±0.03, P＝0.02).
Fig.4  BALF supernatant TNF-αconcentration is shown. BALF TNF-α levels at 30 min after LPS administration in GV and PLV animals are demonstrated. The response of TNF-αin BALF super-
natant was unclear at 30 min after LPS intratracheal administration.
After an additional 2 h of GV or PLV, TNF-αconcentration increased markedly. There was no statistical diﬀerence in TNF-αconcentration between the GV and PLV groups (LPS30 min:637.55±70.0, GV:
19808.5±922.9 vs. PLV:21062.8±1816.3, P＝1.00).
Fig. 5  BALF supernatant MIP-2 concentration is shown. When compared with the negative control group of LPS 30 min, the GV and PLV groups demonstrated signiﬁcant increases in MIP-2. The PLV group seemed to have a higher concentration than that in the GV group, though the diﬀerence between the GV and the PLV groups was not signiﬁcant(LPS 30 min:398.8±64.7, GV:14071.5±809.9 vs.
PLV:16030.3±1663.9, P＝0.64).
Fig.6  BALF supernatant CINC-1 is shown. As was the case for TNF-α and MIP-2, the concentration of CINC-1 demonstrated a signiﬁcant increase in both the GV and PLV group in comparison with levels in the negative control group. No signiﬁcant diﬀerence was observed between the GV and the PLV groups(LPS 30 min:192.6±
41.9, GV:9728.2±1047.4 vs. PLV:11177.1±1411.5, P＝0.6).
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 total cells per ml in the BALF pellet was counted. The total cell counts in both the GV and the PLV groups increased to twice that of the control group(LPS 30 min)
during two hours, though no statistical diﬀerences were found between GV and PLV (LPS 30 min:6825.0±
1435.7, GV:19269.0±3751.6 vs. PLV:16368.0±
2258.8, P＝0.76)(Fig. 7).
The percentage of cells positive for CD11b surface expression among 10000 cells is demonstrated(LPS 30 min:11.2±1.6, GV:63.6±8.4 vs. PLV:60.5±5.4,
P＝0.73) (Fig. 8). Both the GV and PLV groups showed marked increases in the CD11b expression ratio when compared to the negative control group(30-minute group). However, no signiﬁcant diﬀerence in CD11b expression between the GV and PLV groups was identiﬁed.
The percentage of cells positive for anti-rat macro-
phage subset mAb surface expression is demonstrated
(LPS 30 min:3.7±0.5, GV:5.6±1.5 vs. PLV:
14.0±1.3,P＝0.006)(Fig. 9). The positive ratio of the anti-rat macrophage mAb expression in the PLV group was signiﬁcantly greater than that of the GV groups.
Discussion
 
Two rat C-X-C chemokines, MIP-2 and CINC, are generated mainly by macrophages in response to TNF-α
［19, 20］. It is reported that both MIP-2 and CINC result in neutrophil activation and migration［21-23］.
Subsequent neutrophil accumulation and resulting lung injury are reduced by administration of anti-MIP-2 and anti-CINC mAb. Several studies have suggested that pulmonary neutrophil accumulation was also decreased in PLV groups in the setting of lung injury［24-29］.
In this study, we performed no suction from the airway during GV or PLV. Generally, suction of exudate from the lung is performed via intratracheal tube during PLV. A PFC can lavage exudate from the alveoli to the central airway easily because of its large density
 
Fig.7  Total cell count per 1 ml of BALF, measured by Toluidine-
blue O stain, is shown.
Total cell number increased during 2 h of GV or PLV. The PLV group demonstrated a trend to have fewer cells, though there were no statistical diﬀerences between the GV and PLV groups(LPS 30 min:
6825.0±1435.7, GV:19269.0±3751.6 vs. PLV:16368.0±
2258.8, P＝0.76).
Fig.8  CD11b surface expression is shown. CD11b expression is demonstrated as a ratio. The ratio of anti rat CD11b mAb positive cells to total acquired cells (1×10?cells)was calculated. Both the GV and the PLV groups showed marked increases in CD11b expres-
sion in comparison with the negative control. However, there was no statistical diﬀerence between the GV and PLV groups (LPS 30 min:
11.2±1.6, GV:63.6±8.4 vs. PLV:60.5±5.4, P＝0.73).
Fig. 9  An anti-macrophage subset expression is shown. The anti-macrophage subset expression is demonstrated as a ratio. The ratio of anti-macrophage mAb positive cells among total acquired cells (1×10?cells)was calculated. The proportion of macrophage expression was signiﬁcantly higher in the PLV group than in the GV group (LPS 30 min:3.7±0.5, GV:5.6±1.5 vs. PLV:14.0±1.3,
P＝0.006).
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(perﬂubron:1.98 g/ml) and low surface tension. The elimination of exudate,which is thought to be full of these cytokines and chemokines from the lung, is beneﬁcial to prevent the progression of inﬂammation.We thought that the suction of exudate from the airway typically performed during PLV might play an important role. At this point,
we developed the idea of performing no suction from the airway during PLV, and compared the group in which no suction was performed with the GV group.We supposed that PFC might act as a physical barrier for the alveoli by covering its surface, thereby suppressing the inﬂux of inﬂammatory mediator or cells into the alveoli as mentioned earlier. The characteristics of inﬂammatory cells such as neutrophils or macrophages might be chang-
ed by contact with PFC. The CD11b cell surface expres-
sion would be attenuated as a result. If these suppositions were true, CD11b surface expression would be attenuated by PLV, and the production of cytokine as an inﬂammatory mediator in the PLV group, even without any airway suction, would be attenuated as a result.
In this study, we found no signiﬁcant diﬀerence in BALF supernatant TNF-α, MIP-2, or CINC-1 concen-
tration between the GV and the PLV groups. The CD11b cell surface expression was up-regulated in BAL during GV and PLV 2.5 hours after intratracheal LPS administration, though no diﬀerence between the GV and PLV groups was noted. From these results, we suppose that the anti-inﬂammatory eﬀect of PLV in terms of cytokine inhibition is caused mainly by the lavage eﬀect in the in vivo setting. Actually, TNF-α, MIP-2, and CINC-1 concentrations tended to be higher in the PLV group than in the GV group, although there were no signiﬁcant diﬀerences between these groups. To explain this, we came up with three possible explanations. Weiss et al. reported that PFC liquid, when instilled into the lungs intratracheally, might cause transient pulmonary inﬂammatory response in the rodent model［30］. Given that our measurement was performed in the acute phase,
after lung injury had been initiated, this transient inﬂammation is the ﬁrst assumption made by way of explanation. The second assumption is that the distribu-
tion of PFC in alveoli might have helped to ﬂush more cytokine or chemokine when BAL was performed, even if the cytokine accumulated in the lungs was approximate-
ly equal in both GV and PLV groups. The third assump-
tion is that the increased macrophage proportion among BAL cells might be actually associated with increased cytokine and chemokine production.
Several studies have reported reduced production of TNF-αor other cytokines in the in vivo experimental setting of PLV. Our result was contrary to these com-
monly observed results. We speculate that this diﬀerence in results can be mainly attributed to the fact that we performed no suction from the airway during PLV. The descriptions of suction performed during PLV are unclear in many reports on PLV. We consider that a detailed description of the airway suction procedure should be noted.
In our results, the proportion of macrophages among BAL cells was signiﬁcantly increased. It is noted that our result on macrophages did not reﬂect numbers of actual cells. However, based on the result of the BAL total cell count(that there were no diﬀerences between the GV and PLV groups), the actual number of macrophages might be increased in PLV. Van Eeden et al., using a rabbit model, reported the histological ﬁnding of fewer alveolar macrophages in the PLV group than in other groups
［31］. The reason our results diﬀered from theirs is unknown, though there are some diﬀerences in details of the study models such as duration of PLV. We regret that we did not perform a cell diﬀerentiation count when getting the BAL samples and conduct a histological analysis.
Our experimental model was the LPS intratracheal administration model. Intratracheal endotoxin administra-
tion causes an inﬂammatory lung injury that results in the rapid recruitment of activated white cells to the lungs and the production of TNF-α and other proinﬂammatory cytokines［17, 32］. In our preliminary experiment, there were no signiﬁcant diﬀerences in blood pressure or arterial blood gas analysis up to 3 hours after LPS administra-
tion. Therefore, we did not perform these measurements to eliminate other factors, such as blood loss, which can inﬂuence sensitive cytokine measurements. The concen-
tration of TNF-α, MIP-2, and CINC-1 increased markedly in 2.5 hours after LPS intratracheal administra-
tion, but this duration may not be enough to cause changes in these physiological data.
A discussion can be raised at this point about the duration of PLV for 2 hours, and about the timing of initiating PLV at 30 minutes after LPS administration.
Apparently, 2-hours duration is not suﬃcient for inﬂammation to be completed in the lungs. And it is impossible, in fact, to start PLV 30 minutes after lung injury occurs in actual clinical settings. The aim of this study was to manifest the mechanism underlying the
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anti-inﬂammatory eﬀect of PLV, not to mimic the clinical settings. Thus, we tried to start PLV before completion of inﬂammation in the lungs, then performed BAL to measure cytokines and chemokines at the peak point of response. Baba et al. reported that the inhibitory eﬀect of PLV on IL-8 was more apparent when PFC was added earlier in the in vitro setting［33］. And for cytokine and chemokine measurement, it was necessary to obtain samples at the time of peak elevation;that is, at 2 hours.
Our result that CD11b surface expression was not aﬀected by PLV was somewhat surprising to us. Varani et al. suggested that PFC reduces neutrophil-mediated injury to epithelial cells only if PFC is present at the time at which the neutrophils are added to the target cells［34］.
When the neutrophils are added to epithelial cell monolayers and are stimulated prior to PFC administra-
tion, no protective eﬀect for the lungs was present. Thus,
as an explanation for our result of CD11b surface expres-
sion, the neutrophils might have already been primed by LPS in the initial 30 minutes. Thus, even though PFC was administered into the lungs, the surface expression of CD11b might have already been established, and was therefore not altered by the contact with PFC.
In summary, PLV does not aﬀect CD11b cell surface marker up-regulation when started 30 minutes after LPS intratracheal administration. PLV caused no signiﬁcant attenuation in the BALF supernatant TNF-α, MIP-2,
or CINC-1 concentration when no airway suction was performed during PLV. The proportion of macrophages among BAL cells was increased by PLV. From these results, we conclude that anti-inﬂammatory eﬀect of PLV is not caused by the change in CD11b expression, and that PLV aﬀects the proportion of macrophages among BAL cells. Our future study will include investigation of the lavage eﬀect of PLV.
Elucidation of the mechanism of PLV’s anti-
inﬂammatory eﬀect is important for obtaining maximum beneﬁt of PLV in a clinical setting.
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